Quick Answer
Emergent BioSolutions Inc. reported Research And Development Expense of $70.70 million for the year ending 2024.
- Emergent BioSolutions Inc. showed a decrease of -36.5% in Research And Development Expense from 2023 to 2024.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2009 to 2024), Emergent BioSolutions Inc.'s Research And Development Expense has declined by 5.2%.
- Historical annual values: Fiscal year 2024: $70.70 million | Fiscal year 2023: $111.40 million | Fiscal year 2022: $188.30 million | Fiscal year 2021: $235.20 million | Fiscal year 2020: $234.50 million | Fiscal year 2019: $226.20 million | Fiscal year 2018: $142.80 million | Fiscal year 2017: $97.40 million | Fiscal year 2016: $106.90 million | Fiscal year 2015: $119.19 million | Fiscal year 2014: $104.72 million | Fiscal year 2013: $119.93 million | Fiscal year 2012: $120.23 million | Fiscal year 2011: $124.83 million | Fiscal year 2010: $89.30 million | Fiscal year 2009: $74.59 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: